Global Infectious Disease Point of Care Diagnostics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

 Published On: Nov, 2017 |    No of Pages: 211 |  Published By: Precision Business Insights | Format: PDF
Request Free Sample
Point of care diagnostics refers to the tests carried at site of the patient care to provide the immediate results. These diagnostics improve the disease management and detection. Infectious diseases are caused by various microorganisms such as virus, bacteria, fungi, and parasites. Infectious disease point of care diagnostics reduces the time between disease testing and diagnosis of an infection. Nowadays most of the infectious diseases such as HIV, tuberculosis, influenza, tropical diseases, and sexually transmitted infections are diagnosed by the point of care testing. The major advantages with the point of care testing are reduced in diagnosis time, postoperative care time, improvement in disease outcomes, accuracy in results, and simple methods for diagnosis of the infectious diseases.

Increase in the incidence and prevalence of infectious diseases such as malaria, dengue, HIV, rise in healthcare expenditure, growing investments from public and private sectors for the development of new products, rising government support towards the adoption of point of care devices are expected to drive global infectious disease point of care diagnostics market over the forecast period. Moreover, the technological advancements in point of care diagnostic devices and introduction of home-based point of care devices are also anticipated to boost the infectious disease point of care diagnostics market. However, reluctance among the patients to change in existing diagnostic practices, stringent regulatory policies, and reimbursement issues might restrain the growth of global infectious disease point of care diagnostics market over the forecast timeframe.

The infectious disease point of care diagnostics market segmented based on product type, disease condition, prescription mode, and end users.

Based on product type, the infectious disease point of care diagnostics market segmented into the following:

Infectious disease testing kits & Reagents
Hepatitis
HIV infection
Respiratory infections
Influenza
Sexually-transmitted diseases (STDs) infection
Others
Haematology testing kits
Urinalysis Testing Kits
Others

Based on disease condition, the infectious disease point of care diagnostics market segmented into the following:

Bacterial Infection
Fungal infection
Viral Infection
Cardiovascular infection
GI infections
Sexually transmitted disease
CNS infections
Other

Based on prescription mode, the infectious disease point of care diagnostics market segmented into the following:

Over-the-counter (OTC) Testing Kits
Prescription-based Testing Kits

Based on end-user, the infectious disease point of care diagnostics market segmented into the following:

Professional diagnostic centres
Hospitals
Outpatient healthcare Setting
Homecare
Others

The global infectious disease point of care diagnostics market is in the flourishing stage as several local and international players are actively involved in the development of infectious disease point of care diagnostic devices. Increase in the prevalence of the deadly infectious disease will drive the growth of the global infectious disease point of care diagnostics market. For instance, according to World Health Organisation, global health observatory (GHO) data, in 2013, approximately 34-38 million people suffered from HIV infection worldwide. Launching of new products, approvals from various regulatory bodies, acquisitions and mergers, partnerships, collaborations, and joint ventures are expected to fuel the growth of global infectious disease point of care diagnostics market over the forecast period. For instance, in January 2015, FDA has approved Alere for its first CLIA waiver for the nucleic acid-based test, Influenza A&B. Further Roche’s CLIA waiver for Cobas Liat System and Strep A. By 2016, many systems received CLIA waivers from FDA including the Xpert Flu/RSV Xc by Cepheid’s.

Geographically, global infectious disease point of care diagnostics market has been segmented into following regions Viz. North America, Latin America, Europe, Middle East & Africa and Asia-Pacific. North-America holds a key share in global infectious disease point of care diagnostics market is due to increase in the prevalence of infectious diseases especially in U.S. (according to UNAIDS, in 2012, about 1.3Mn patients were diagnosed with HIV within the U.S.). These statistics are likely to increase over the coming years if suitable treatment options are not provided in time. The European region is also a major region for the growth of global infectious disease point of care diagnostics market due to improved healthcare infrastructure, and increase in prevalence of bacterial and viral diseases (according to WHO European Region, at the end of 2015, about 13.3 Mn people live with chronic hepatitis B, an estimated 15 Mn people with hepatitis C, and more than 2 Mn people with HIV). Moreover, Asia-Pacific region holds a significant growth in infectious disease point of care diagnostics market owing to the high prevalence of infectious diseases, unhygienic environment, and huge investment opportunities due to increase in healthcare expenditure. Moreover, due to high prevalence and incidence of infectious diseases especially sexually transmitted disease and bacterial infections, and high population - the growth of global infectious disease point of care diagnostics market expected to fuel in the Asia-Pacific region.

Some of the players in the global infectious disease point of care diagnostics market are Cepheid Inc. (Danaher Corporation) (U.S.), Abbott Laboratories, Inc. (U.S.), F. Hoffmann La Roche Limited (Switzerland), Beckman Coulter, Inc. (U.S.), Siemens AG (Germany), Johnson & Johnson Services, Inc. (U.S.), Instrumentation Laboratory (U.S.), Becton, Dickinson and Company (U.S.), Alere Inc. (U.S.), Nova Biomedical (U.S.), Thermo Fisher Scientific Inc. (U.S.), and Quidel Corporation (U.S.) to name a few.

In 2014, in the cardiovascular space, Spartan Biosciences had received approval from Health Care Canada for its genetic test, Spartan RX CYP2C19 system

In 2014, Roche bought point of care molecular testing company iQuum for $275 million and the potential for an additional $175 million in milestone payments

Report Outline:

The report provides granular level information about the market size, regional market share and forecast from 2017-2023
The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
The report tracks recent innovations, key developments and startup’s details that are working in the industry
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
1. Executive summary
2. Global Infectious Disease Point of Care Diagnostics Market Introduction
2.1. Global Infectious Disease Point of Care Diagnostics Market– Taxonomy
2.2. Global Infectious Disease Point of Care Diagnostics Market–Definitions
2.2.1. End User
2.2.2. Product Type
3. Global Infectious Disease Point of Care Diagnostics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Infectious Disease Point of Care Diagnostics Market Dynamics – Factors Impact Analysis
3.6. Global Infectious Disease Point of Care Diagnostics Market– Recent Product Launches
4. Global Infectious Disease Point of Care Diagnostics Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. Global Infectious Disease Point of Care Diagnostics Market Forecast, By Product Type, 2012 - 2016 and Forecast, 2017 - 2023
5.1. Infectious Disease Testing Kits & Reagents
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Haematology Testing Kits
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Urinalysis Testing Kits
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Others
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
6. Global Infectious Disease Point of Care Diagnostics Market Forecast, By Disease Condition, 2012 - 2016 and Forecast, 2017 - 2023
6.1. Bacterial Infections
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Fungal Infections
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Viral Infections
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Cardiovascular Infections
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. GI Infections
6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Sexually Transmitted Disease
6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. CNS Infections
6.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
6.8. Others
6.8.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.8.3. Market Opportunity Analysis
7. Global Infectious Disease Point of Care Diagnostics Market Forecast, By Prescription Mode, 2012 - 2016 and Forecast, 2017 - 2023
7.1. Over-the-counter (OTC) Testing Kits
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Prescription-based Testing Kits
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
8. Global Infectious Disease Point of Care Diagnostics Market Forecast, By End User, 2012 - 2016 and Forecast, 2017 - 2023
8.1. Professional Diagnostic Centers
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Homecare
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Others
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
9. Global Infectious Disease Point of Care Diagnostics Market Forecast, By Region, 2012 - 2016 and Forecast, 2017 - 2023
9.1. North America
9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Infectious Disease Point of Care Diagnostics Market- Opportunity Analysis Index - By Product Type, By Disease Condition, By Prescription Mode, By End User, and Region, 2017 – 2023
10. North America Infectious Disease Point of Care Diagnostics Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
10.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.1.1. Infectious Disease Testing Kits & Reagents
10.1.1.1.1. Hepatitis
10.1.1.1.2. HIV Infection
10.1.1.1.3. Respiratory Infections
10.1.1.1.4. Influenza
10.1.1.1.5. Sexually-Transmitted Diseases (STDs)
10.1.1.1.6. Others
10.1.1.2. Haematology Testing Kits
10.1.1.3. Urinalysis Testing Kits
10.1.1.4. Others
10.1.2. Disease Condition Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. Bacterial Infections
10.1.2.2. Fungal Infections
10.1.2.3. Viral Infections
10.1.2.4. Cardiovascular Infections
10.1.2.5. GI Infections
10.1.2.6. Sexually Transmitted Disease
10.1.2.7. CNS Infections
10.1.2.8. Other
10.1.3. Prescription Mode Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Over-The-Counter (OTC) Testing Kits
10.1.3.2. Prescription-based Testing Kits
10.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Professional Diagnostic Centres
10.1.4.1.1. Hospitals
10.1.4.1.2. Outpatient Healthcare Setting
10.1.4.2. Homecare
10.1.4.3. Others
10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.1.5.1. U.S.
10.1.5.2. Canada
10.1.6. North America Infectious Disease Point of Care Diagnostics Market- Opportunity Analysis Index - By Product Type, By Disease Condition, By Prescription Mode, By End User, and Country, 2017 – 2023
10.1.7. North America Infectious Disease Point of Care Diagnostics Market Dynamics – Trends
11. Europe Infectious Disease Point of Care Diagnostics Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
11.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.1.1. Infectious Disease Testing Kits & Reagents
11.1.1.1.1. Hepatitis
11.1.1.1.2. HIV Infection
11.1.1.1.3. Respiratory Infections
11.1.1.1.4. Influenza
11.1.1.1.5. Sexually-Transmitted Diseases (STDs)
11.1.1.1.6. Others
11.1.1.2. Haematology Testing Kits
11.1.1.3. Urinalysis Testing Kits
11.1.1.4. Others
11.1.2. Disease Condition Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. Bacterial Infections
11.1.2.2. Fungal Infections
11.1.2.3. Viral Infections
11.1.2.4. Cardiovascular Infections
11.1.2.5. GI Infections
11.1.2.6. Sexually Transmitted Disease
11.1.2.7. CNS Infections
11.1.2.8. Other
11.1.3. Prescription Mode Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Over-The-Counter (OTC) Testing Kits
11.1.3.2. Prescription-based Testing Kits
11.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.4.1. Professional Diagnostic Centres
11.1.4.1.1. Hospitals
11.1.4.1.2. Outpatient Healthcare Setting
11.1.4.2. Homecare
11.1.4.3. Others
11.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.5.1. Germany
11.1.5.2. UK
11.1.5.3. France
11.1.5.4. Spain
11.1.5.5. Italy
11.1.5.6. Russia
11.1.5.7. Poland
11.1.5.8. Rest of Europe
11.1.6. Europe Infectious Disease Point of Care Diagnostics Market- Opportunity Analysis Index - By Product Type, By Disease Condition, By Prescription Mode, By End User, and Country, 2017 – 2023
11.1.7. Europe Infectious Disease Point of Care Diagnostics Market Dynamics – Trends
12. Asia-Pacific Infectious Disease Point of Care Diagnostics Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
12.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.1.1. Infectious Disease Testing Kits & Reagents
12.1.1.1.1. Hepatitis
12.1.1.1.2. HIV Infection
12.1.1.1.3. Respiratory Infections
12.1.1.1.4. Influenza
12.1.1.1.5. Sexually-Transmitted Diseases (STDs)
12.1.1.1.6. Others
12.1.1.2. Haematology Testing Kits
12.1.1.3. Urinalysis Testing Kits
12.1.1.4. Others
12.1.2. Disease Condition Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. Bacterial Infections
12.1.2.2. Fungal Infections
12.1.2.3. Viral Infections
12.1.2.4. Cardiovascular Infections
12.1.2.5. GI Infections
12.1.2.6. Sexually Transmitted Disease
12.1.2.7. CNS Infections
12.1.2.8. Other
12.1.3. Prescription Mode Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Over-The-Counter (OTC) Testing Kits
12.1.3.2. Prescription-based Testing Kits
12.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Professional Diagnostic Centres
12.1.4.1.1. Hospitals
12.1.4.1.2. Outpatient Healthcare Setting
12.1.4.2. Homecare
12.1.4.3. Others
12.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
12.1.5.1. Japan
12.1.5.2. China
12.1.5.3. India
12.1.5.4. ASEAN
12.1.5.5. Australia & New Zealand
12.1.5.6. Rest of Asia-Pacific
12.1.6. Asia-Pacific Infectious Disease Point of Care Diagnostics Market- Opportunity Analysis Index - By Product Type, By Disease Condition, By Prescription Mode, By End User, and Country, 2017 – 2023
12.1.7. Asia-Pacific Infectious Disease Point of Care Diagnostics Market Dynamics – Trends
13. Latin America Infectious Disease Point of Care Diagnostics Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
13.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.1.1. Infectious Disease Testing Kits & Reagents
13.1.1.1.1. Hepatitis
13.1.1.1.2. HIV Infection
13.1.1.1.3. Respiratory Infections
13.1.1.1.4. Influenza
13.1.1.1.5. Sexually-Transmitted Diseases (STDs)
13.1.1.1.6. Others
13.1.1.2. Haematology Testing Kits
13.1.1.3. Urinalysis Testing Kits
13.1.1.4. Others
13.1.2. Disease Condition Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.2.1. Bacterial Infections
13.1.2.2. Fungal Infections
13.1.2.3. Viral Infections
13.1.2.4. Cardiovascular Infections
13.1.2.5. GI Infections
13.1.2.6. Sexually Transmitted Disease
13.1.2.7. CNS Infections
13.1.2.8. Other
13.1.3. Prescription Mode Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Over-The-Counter (OTC) Testing Kits
13.1.3.2. Prescription-based Testing Kits
13.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.4.1. Professional Diagnostic Centres
13.1.4.1.1. Hospitals
13.1.4.1.2. Outpatient Healthcare Setting
13.1.4.2. Homecare
13.1.4.3. Others
13.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.5.1. Brazil
13.1.5.2. Mexico
13.1.5.3. Argentina
13.1.5.4. Venezuela
13.1.5.5. Rest of Latin America
13.1.6. Latin America Infectious Disease Point of Care Diagnostics Market- Opportunity Analysis Index - By Product Type, By Disease Condition, By Prescription Mode, By End User, and Country, 2017 – 2023
13.1.7. Latin America Infectious Disease Point of Care Diagnostics Market Dynamics – Trends
14. Middle East & Africa Infectious Disease Point of Care Diagnostics Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
14.1.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.1.1.1. Infectious Disease Testing Kits & Reagents
14.1.1.1.1. Hepatitis
14.1.1.1.2. HIV Infection
14.1.1.1.3. Respiratory Infections
14.1.1.1.4. Influenza
14.1.1.1.5. Sexually-Transmitted Diseases (STDs)
14.1.1.1.6. Others
14.1.1.2. Haematology Testing Kits
14.1.1.3. Urinalysis Testing Kits
14.1.1.4. Others
14.1.2. Disease Condition Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.1.2.1. Bacterial Infections
14.1.2.2. Fungal Infections
14.1.2.3. Viral Infections
14.1.2.4. Cardiovascular Infections
14.1.2.5. GI Infections
14.1.2.6. Sexually Transmitted Disease
14.1.2.7. CNS Infections
14.1.2.8. Other
14.1.3. Prescription Mode Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.1.3.1. Over-The-Counter (OTC) Testing Kits
14.1.3.2. Prescription-based Testing Kits
14.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.1.4.1. Professional Diagnostic Centres
14.1.4.1.1. Hospitals
14.1.4.1.2. Outpatient Healthcare Setting
14.1.4.2. Homecare
14.1.4.3. Others
14.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.5.1. Gulf Cooperation Council (GCC) Countries
14.1.5.2. Israel
14.1.5.3. South Africa
14.1.5.4. Rest of MEA
14.1.6. MEA Infectious Disease Point of Care Diagnostics Market- Opportunity Analysis Index - By Product Type, By Disease Condition, By Prescription Mode, By End User, and Country, 2017 – 2023
14.1.7. MEA Infectious Disease Point of Care Diagnostics Market Dynamics – Trends
15. Competition Landscape
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Cepheid Inc. (Danaher Corporation) (U.S.)
15.2.2. Abbott Laboratories, Inc. (U.S.)
15.2.3. F. Hoffmann La Roche Limited (Switzerland)
15.2.4. Beckman Coulter, Inc. (U.S.)
15.2.5. Siemens AG (Germany)
15.2.6. Johnson & Johnson Services, Inc. (U.S.)
15.2.7. Instrumentation Laboratory (U.S.)
15.2.8. Becton, Dickinson and Company (U.S.)
15.2.9. Alere Inc. (U.S.)
15.2.10. Nova Biomedical (U.S.)
15.2.11. Thermo Fisher Scientific Inc. (U.S.)
15.2.12. Quidel Corporation (U.S.)
16. Research Methodology
17. Key Assumptions and Acronyms

If the above report does not have the information suitable for your business, we can provide custom research that can be lucrative for your business or enhance your profession.